KBY Biotech Indexv0.0.34
Search
← Pipeline|600-1765

600-1765

Approved
By Jiangsu Hengrui
Source: Trial-derived·Trials: 1
Modality
Radioligand
MOA
Cl18.2
Target
B7-H3
Pathway
RAS/MAPK
OCD
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
~Jun 2019
→ ~Sep 2020
Phase 3
~Dec 2020
→ ~Mar 2022
NDA/BLA
~Jun 2022
→ ~Sep 2023
Approved
Dec 2023
ApprovedCurrent
NCT05223842
1,129 pts·OCD
2023-12→TBD·Active
1,129 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Approved
Active
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05223842ApprovedOCDActive1129PFS
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-4358Eli LillyPhase 3B7-H3CFTRmod
CeviglumideRocheNDA/BLAB7-H3CD47i
ZorivorutinibBristol-Myers SquibbApprovedDLL3Cl18.2
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
SNY-8628SanofiNDA/BLAB7-H3TYK2i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
NVO-7840Novo NordiskPhase 2/3B7-H3GLP-1ag
NVO-7872Novo NordiskNDA/BLAB7-H3BTKi
DSN-5254Daiichi SankyoPhase 1B7-H3ALKi
DatozumabRegeneronPhase 1B7-H3USP1i